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Individuals with Down syndrome (DS) are more likely to experience earlier onset of multiple facets of
physiological aging. This includes brain atrophy, beta amyloid deposition, cognitive decline, and Alz-
heimer’s diseasedfactors indicative of brain aging. Here, we employed a machine learning approach,
using structural neuroimaging data to predict age (i.e., brain-predicted age) in people with DS (N ¼ 46)
and typically developing controls (N ¼ 30). Chronological age was then subtracted from brain-predicted
age to generate a brain-predicted age difference (brain-PAD) score. DS participants also underwent [11C]-
PiB positron emission tomography (PET) scans to index the levels of cerebral beta amyloid deposition,
and cognitive assessment. Mean brain-PAD in DS participants’ was þ2.49 years, signiﬁcantly greater than
controls (p < 0.001). The variability in brain-PAD was associated with the presence and the magnitude of
PiB-binding and levels of cognitive performance. Our study indicates that DS is associated with pre-
mature structural brain aging, and that age-related alterations in brain structure are associated with
individual differences in the rate of beta amyloid deposition and cognitive impairment.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Down syndrome (DS), the result of trisomy 21, results in in-
tellectual disability and a set of characteristic physiological and
behavioral traits. In middle adulthood, people with DS also
commonly experience clinical symptoms that are normally asso-
ciated with older age (Covelli et al., 2016; Devenny et al., 2005).
Whether DS truly results in an acceleration to all aspects of the
aging process is controversial (Zigman, 2013). Nevertheless, skin
wrinkles, gray hair and alopecia, visual and auditory decline,
hypogonadism, hypothyroidism, osteoporosis, and the menopause
all occur considerably earlier in people with DS (Covelli et al.,
2016; Zigman, 2013). Beside these physiological manifestations
of aging, evidence also suggests that people with DS experiencegton Danes Building, Ham-
UK. Tel.: þ44 20 7594 7994;
le).
Inc. This is an open access articlepremature brain aging. Cognitive decline and subsequent Alz-
heimer’s Disease (AD) occur more frequently and at an earlier age
in DS (Devenny et al., 2000; Holland et al., 1998; Margallo-Lana
et al., 2007; Wisniewski et al., 1985). In addition, postmortem
and in vivo studies show increased cerebral beta amyloid depo-
sition, neuroﬁbrillary tau tangles, brain atrophy, and white matter
lesions in DS (Annus et al., 2016; Head et al., 2016; Lao et al., 2016;
Mann and Esiri, 1989; Nelson et al., 2011; Roth et al., 1996;
Wisniewski et al., 1985). All these changes have been associated
with the typically aging brain, albeit at an older age (Braskie et al.,
2010; Fjell et al., 2009; Jack et al., 2014; Rodrigue et al., 2012;
Wardlaw et al., 2013). However, despite this increased preva-
lence of “age-like” changes observed in people with DS, the onset
of the symptoms of brain aging and subsequent trajectories of
decline show marked variability (Oliver et al., 1998). While the
biological mechanisms underlying these brain changes in DS are
likely distinct from normal aging, their manifestation can still be
assessed using the same techniques, such as neuroimaging.
Therefore, understanding the relationships among beta amyloidunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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capture these individual differences and allow better prediction of
health outcomes.
Tomeasure how brain structure changeswith aging, multivariate
machine learningmethods have been developed that allow accurate
prediction of chronological age using neuroimaging data
(Dosenbach et al., 2010; Franke et al., 2010;Mwangi et al., 2013). This
has demonstrated that neuroimaging data can be used to generate
an index that quantiﬁes age-related changes to brain volume, which
we refer to as “brain-predicted age.” Accordingly, brain-predicted
age, or equivalent, has been used to demonstrate that environ-
mental factors are associated with a person’s brain appearing
younger or older thanwould be expected for their chronological age.
Deleterious inﬂuences on brain-predicted age include traumatic
brain injury (Cole et al., 2015), obesity (Ronan et al., 2016), schizo-
phrenia (Koutsouleris et al., 2014; Schnack et al., 2016), HIV infection
(Cole et al., 2017), diabetes (Franke et al., 2013), mild cognitive
impairment, and AD (Franke and Gaser 2012; Gaser et al., 2013).
Conversely, the protective effects of physical exercise, education, and
meditation (Luders et al., 2016; Steffener et al., 2016) have also been
reported, indicating that brain-predicted age can deviate outside of
the context of atrophy due to brain diseases. The variability in brain-
predicted age appears to be a useful way of quantifying individual
differences in structural age-related changes to the brain in both
disease and the general population.
Here, we sought to establish if people with DS show evidence
of premature brain aging, using neuroimaging to measure brain-
predicted age. Furthermore, we considered whether levels of
beta amyloid deposition (according to positron emission tomog-
raphy [PET] imaging), cognitive decline, and the manifestation of
dementia relate to the levels of “age-like” changes to brain
structure in DS.
2. Materials and methods
2.1. Participants
The study included N ¼ 46 adults with DS (mean age ¼ 42.30 
8.73 years, 25 males/21 females) and N ¼ 30 typically developing
adults as a control group (mean age ¼ 46.23  9.75, 16 males/14
females). All 76 individuals underwent MRI scans, while the DS
group also underwent PET scans. Data on these individuals have
been previously reported (Annus et al., 2016). All DS participants
have previously received a clinical diagnosis of DS based on having
the characteristic phenotype, while a proportion (N ¼ 33) were
karyotyped to conﬁrm the presence of trisomy 21. Participants were
screened to ensure that they had no contraindications to MRI and
PET scanning. Ethical approval for the study was granted by the
National Research Ethics Committee of East of England and the
Administration of Radioactive Substances Advisory Committee
(ARSAC). Written consent was obtained from all adults with DS
with the capacity to consent. For participants lacking the capacity to
consent, the procedures set out in the England and Wales Mental
Capacity Act (2005) were followed. These 76 individuals comprised
the brain-predicted age test set.
To deﬁne a multivariate model of healthy brain structure across
the lifespan, datawere collated from publicly available sources. This
included N ¼ 2001 typically developing, healthy individuals (mean
age ¼ 36.95  18.12, age range 18e90 years, 1016 males/985 fe-
males), who comprised the brain-predicted age training set (see
Supplementary Table 1). All training set participants were screened
locally to exclude individuals with major neurologic or psychiatric
diagnoses, a history of head trauma or major physical health
problems, as per local study protocols. Each contributing study was
granted ethical approval for data collection and subsequent datasharing. Informed consent was obtained at each local study site in
accordance with local guidelines.
2.2. Clinical and neuropsychological assessment
All DS participants were assessed for dementia using an infor-
mant interview; the Cambridge Examination for Mental Disorders
of the Elderly-DS version (CAMDEX-DS), adapted from the original
CAMDEX for diagnosing dementia speciﬁcally in DS (Ball et al.,
2004). These informant interviews were conducted by trained re-
searchers at the University of Cambridge. Subsequently, an expe-
rienced clinician (SHZ), who was blinded to participant identity,
used interview transcripts to assign DS participants to 1 of the 3
discrete categories: cognitively stable, cognitive decline, or de-
mentia. Classiﬁcation of dementia was in line with established
criteria (International Classiﬁcation of Disease 10). Cognitive
decline was deﬁned as evidence of cognitive impairment in one or
more cognitive domains without fulﬁlling the full criteria for de-
mentia. As part of the CAMDEX, all participants in the DS group
underwent the Cambridge Cognitive Examination (CAMCOG;
Holland et al., 1998). The CAMCOG collates functioning across a
range of cognitive domains and generates a continuous measure of
cognitive function, where higher scores indicate higher levels of
cognitive performance. Three DS participants were unable to
complete the CAMCOG assessment, due to having advanced
symptoms of dementia.
2.3. Apolipoprotein E genotyping
DS participants supplied blood samples that were processed to
determine the genotypes for apolipoprotein E (APOE). Peripheral
blood samples were stored in EDTA tubes and the DNA extracted
using standard methods. The DNA was genotyped for ApoE using
primer pairs to amplify by polymerase chain reaction (PCR) the
region containing the Arg/Cys polymorphism at codons 112 and 158
of the APOE gene. Standard PCR was performed using PCR mix
(Bioline) using Taq polymerase to unambiguous typing of all
homozygotic and heterozygotic isoform combinations. For analysis
purposes, APOE genotype was used to deﬁne a binary categoriza-
tion of each participant as either an e4 carrier or not an e4 carrier.
APOE data were missing for N ¼ 6 DS participants, from whom
blood samples could not be collected.
2.4. Neuroimaging data acquisition
Full details of the PET acquisition protocol have been previously
reported (Annus et al., 2016). In brief, PET data were acquired using
a GE Advance scanner (General Electric Medical Systems, Milwau-
kee, WI, USA) to measure the levels of [11C]-Pittsburgh compound B
(PiB) uptake across the brain. [11C]-PiB was injected as a bolus via a
catheter and data were acquired for 90 minutes after injection.
Fifty-eight frames were acquired as follows: 18  5 seconds, 6 
15 seconds, 10  30 seconds, 7  60 seconds, 4  150 seconds, and
13  300 seconds. Sinogram data were then reconstructed, result-
ing in a voxel size of 2.34 2.34 4.25mm. Visual inspection of the
PET data was conducted to ensure that there were no major head
movements or other artifacts present.
Structural images were T1-weighted MRI scans, acquired for the
DS and control groups using the same Siemens Verio 3T scanner
(Siemens AG, Erlangen, Germany). A magnetization-prepared rapid
gradient echo (MPRAGE) sequence was used, with the following
parameters: TR ¼ 2300 ms, TE ¼ 2.98 ms, TI ¼ 900 ms, ﬂip
angle ¼ 9, and matrix dimension ¼ 256  240. The protocol
acquired 176 axial slices of 1 mm thickness, resulting in voxels of
1 mm3. Parallel acceleration was not enabled.
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training dataset, collated from previous studies. All training data
were acquired at either 1.5T or 3T using standard T1-weighted
sequences (e.g., MPRAGE, SPGR, T1-FFE).
2.5. PiB binding analysis
To measure [11C]-PiB uptake levels across the brain, non-
displaceable binding potential (BPND) was calculated for different
cerebral regions of interest (ROIs). This process involved 2 stages:
the delineation of ROIs using T1-MRI and then the extraction of
mean PiB BPND levels for each ROI from the PET data (as per Annus
et al., 2016). To delineate cortical ROIs, a customized Brodmann
atlas, registered to the Colin27 T1 template, was warped to a study-
speciﬁc T1 template. This process was achieved using the Advanced
Normalisation Tools (ANTS; Avants et al., 2011) and involved skull-
stripping, afﬁne global registration, and an iterative nonlinear local
registration procedure to generate the study-speciﬁc template and
register the atlas to the template. The Colin27-Brodmann atlas was
then resampled to the study template space using nearest neighbor
interpolation. Subcortical ROIs were also included, derived using
FSL FIRST (Patenaude et al., 2011), resulting in a total of 30 ROIs.
FIRST analysis was conducted in participant native space, before
being resampled into study template space, again using nearest
neighbor interpolation for discrete ROI images. To reduce the
inﬂuence of partial volume effects (PVE), T1 images were
segmented (i.e., tissue classiﬁed) using SPM12 (University College
London, London, UK) to generate gray matter (GM), white matter
(WM), and cerebrospinal ﬂuid (CSF) probability images. These
images were also warped to the study-speciﬁc templates using the
ANTS transformations calculated as above.
PET data were also normalized to the study-speciﬁc template.
This involved initially realigning the dynamic PET time-series and
then averaging them across time using SPM12. These mean images
were then rigidly registered to their corresponding native T1 im-
ages (which had been bias-ﬁeld corrected), using ANTS. Then, by
combining together the PET-T1 native and T1-study template
transformations, PET images were normalized to the study tem-
plate using a single resampling step, via trilinear interpolation.
Next, regional PiB BPND values were calculated, using PET data,
cortical and subcortical ROIs, and tissue probability masks, all in
study template space. For each ROI, thresholded at 65% GM
probability, time-activity curves (TACs) were extracted from the
normalized PET data. Tissue-input kinetic modeling was then car-
ried out, using the superior cerebellum as a reference region
(thresholded to 90% GM probability). As a further step to reduce
partial volume effects, each TAC was divided by 1-CSF probability
value in each voxel. The ﬁnal BPND per ROI was then calculated
using a basis function version of the simpliﬁed reference tissue
model (Gunn et al., 1997).
To ascertainwhether an individual’s PET data indicated that they
had abnormal levels of PiB binding (i.e., PiB-status), indicative of
ﬁbrillary beta amyloid deposition, our previously outlined proced-
ure was used (Annus et al., 2016). This entailed deﬁning a bimodal
distribution of striatal (i.e., caudate and putamen) PiB BPND levels.
Individuals with striatal PiB BPND <1 standard deviation (SD) from
0 were deﬁned as PiB-negative, while individuals with striatal PiB
BPND 1 SD from 0 were deﬁned as PiB-positive. Subsequently,
regional PiB BPND was deﬁned as normal or abnormal per partici-
pant, based on the distribution of PiB BPND for a given region in the
PiB-negative group. Abnormal PiB BPND was deﬁned as2 SDs from
the PiB-negative group mean. Finally, the total number of ROIs
deﬁned as abnormal was summed per participant. Notably, in-
dividuals in the PiB-negative group did now show any evidence of
abnormal PiB BPND in nonstriatal ROIs. In addition to classifyingROIs based on PiB BPND, the mean PiB BPND across all cortical ROIs
was calculated.
2.6. Brain-predicted age calculation
An overview of the brain-predicted age calculation procedure is
presented in Fig. 1. All structural images were preprocessed using
SPM12. Images were bias corrected and segmented into GM, WM,
and CSF using SPM Segment. Visual quality control was carried out
at this stage to ensure the accuracy of image segmentation; all
images were included for both groups. Segmented images for GM
and WM were then nonlinearly registered to a custom template,
based on the training dataset, using SPM DARTEL (Ashburner,
2007). Finally, images were afﬁne registered to MNI152 space
(voxel size ¼ 1.5 mm3) and resampled using modulation to retain
volumetric information and smoothed with a 4-mm full-width
half-maximum Gaussian kernel. Summary measures of brain vol-
umes were also generated for GM, WM, CSF, and intracranial vol-
ume (ICV).
Brain-predicted ages were generated as previously outlined
(Cole et al., 2015), using the Pattern Recognition for Neuroimaging
Toolbox (PRoNTo v2.0, www.mlnl.cs.ucl.ac.uk/pronto) software
package. First, a model of healthy brain aging was deﬁned using
brain volumetric maps from the training dataset (N ¼ 2001) as
follows: Spatially normalized images were converted to vectors and
the resulting GM and WM vectors were concatenated for each in-
dividual. A linear kernel representation of these data was derived
by calculating an N  N similarity matrix, where each point in the
matrix was the dot product of 2 participants’ image vectors. A
Gaussian Processes regression model was then deﬁned, with
chronological age as the dependent variable and 3-dimensional
brain volumetric image data (in similarity matrix form) as the in-
dependent variables.
Predictions for all training participants were generated using
10-fold cross-validation, whereby the data were randomly divided
into 10 folds, each comprising 10% of the participants. The model
was then retrained using 9 folds of the data and age predictions
were made for data in the “left-out” fold. This procedure was iter-
ated so that all folds were left out in turn, resulting in unbiased (i.e.,
independent) age predictions for each participant. Model accuracy
was expressed as the correlation between age and brain-predicted
age (Pearson’s r), total variance explained (R2), mean absolute error
(MAE), and root mean squared error (RMSE). Statistical signiﬁcance
of this model was assessed using permutation testing (n ¼ 1000).
Next, the coefﬁcients from the full training model (N ¼ 2001)
were applied to the test data (i.e., DS participants and controls), to
generate unbiased brain-predicted ages. Finally, brain-predicted
age difference (brain-PAD) scores were calculated for each indi-
vidual in the DS and control groups by subtracting chronological
age from brain-predicted age. Hence, a positive brain-PAD score
indicates that the individual’s brain is predicted to be “older” than
their chronological age. Brain-PAD scores were subsequently used
for further analysis to index relative structural brain aging.
2.7. Statistical analysis
Using brain-PAD values, further statistical analysis was con-
ducted to compare the experimental groups and assess the re-
lationships between variables. Datawere assessed for normality and
parametric tests deemed appropriate for use. Fisher’s exact tests
were used to compare the frequencies of categorical variables,
Pearson’s correlations were used to relate continuous variables and
t-tests were used to compare means between groups. A linear
regression model was run with brain-PAD as the outcome variable
and group as the predictor, to compare brain-PAD between DS
Fig. 1. Overview of the brain-predicted age analysis pipeline. Illustration of the methods used to generate brain-predicted ages. 3D T1-weighted MRI scans were segmented into
gray matter (GM) and white matter (WM) before being normalized to common space using nonlinear image registration. Normalized GM and WM images were concatenated and
converted into vectors for each participant. These vectors were then projected into an N  N similarity matrix based on vector dot-products. (A) Once in similarity matrix form, the
training participants’ data were used as predictors in a Gaussian Processes regression model with age as the outcome variable. (B) Model accuracy was assessed in a 10-fold cross-
validation procedure, comparing brain-predicted age with original chronological age labels. (C) Model coefﬁcients learned during training were then applied to the data from DS
participants and controls to generate brain-predicted ages. (D) A metric to summarize the variation in brain-predicted age was deﬁned; the brain-predicted age difference.
Abbreviation: brain-PAD, brain-predicted age difference.
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compare ICV between groups. To establish whether brain-PAD
predicted characteristics of the DS participants, logistic regressions
for categorical outcome variable (PiB-status, CAMDEX classiﬁcation)
and linear regressions for continuous outcome variable (mean
BPND, number of PiB-abnormal ROIs, and CAMCOG score) models
were run, with age as a covariate. All statistical analysis of brain-PAD
was conducted using R v3.3 (R Core Team, 2015).
3. Results
3.1. Cohort description
Compared to controls, DS participants were trending toward
being younger (Table 1, p¼ 0.08), while the ratio ofmales to females
was similar between groups (p ¼ 0.96). DS participants who were
positive for PiB-binding were older than PiB-negative counterparts
(p < 0.001) and had higher rates of cognitive decline and dementia
according to CAMDEX classiﬁcation (p < 0.001), though similar
levels of cognitive performance, according to the CAMCOGTable 1
Characteristics of Down syndrome participants and controls
Characteristic DS (all)
N 46
Mean age (y) 42.3 (8.73)
Age range (y) 28e65
Sex (male/female) 25/21
CAMDEX classiﬁcation (stable, declining, dementia) 31/6/9
CAMCOG score 74.37 (20.01)
APOE genotype (e2/e3, e2/e4, e3/e3, e3/e4/missing) 8/2/20/10/6
Values presented in the table are either N, or in mean (standard deviation) form.assessment (p ¼ 0.33). There was no relationship between
PiB-status and sex (p ¼ 0.78).
3.2. Age can be accurately predicted using neuroimaging
The machine learning model accurately predicted chronological
age in the training dataset, based on T1-weighted MRI. Ten-fold
cross-validation resulted in a correlation between brain-predicted
age and chronological age of r ¼ 0.94 (p ¼ 0.001, corrected after
1000 permutations) and explained 88% of the variance (R2). The
MAE of prediction ¼ 5.02 years and the RMSE ¼ 6.31 years. This
training stage validated our model of brain-predicted age for use in
predicting age with neuroimaging data in the test set, comprising
DS participants and controls.
3.3. Down syndrome is associated with increased brain-predicted
age difference
Brain-PAD in DS participants was signiﬁcantly greater than
controls (b ¼ 7.69 [95% conﬁdence intervals ¼ 4.3, 11.1], SE ¼ 1.72,DS PiB-positive DS PiB-negative Controls
19 27 30




70.19 (22.98) 76.85 (18.03) -
4/1/6/5/3 4/1/14/5/3 -
Fig. 2. Brain-predicted age in individuals with Down syndrome (DS) and controls. (A) Box plot of brain-PAD (years) according to group, showing DS participants (red box) and
controls (blue box). Whiskers (i.e., bars) on the box plots represent the absolute range of data points for each group. (B) Scatterplot of age (x-axis) and brain-predicted age (y-axis)
indicates DS participants (red circles) and controls (blue controls). Plotted are linear regression lines representing a linear ﬁt of age regressed onto brain-predicted each, colored
according to group (DS ¼ red line, control ¼ blue line). Abbreviation: brain-PAD, brain-predicted age difference. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the Web version of this article.)
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2.49 years (SD ¼ 8.25), while in the control group mean brain-PAD
was 5.20 years (SD ¼ 5.67). Brain-PAD in the DS group was
signiﬁcantly greater than the training set mean (t ¼ 2.04, p ¼ 0.04).
Brain-predicted age was signiﬁcantly correlated with chronological
age in both DS participants (r ¼ 0.72, p < 0.001) and in controls
(r¼ 0.91, p< 0.001, Fig. 2B). There were no differences in prediction
accuracy between groups (p ¼ 0.91), with the MAE in DS ¼ 6.65
(SD¼ 8.20) years and in controls MAE¼ 6.46 (SD ¼ 5.67) years. The
RMSE ¼ 8.53 in DS and 7.62 in controls.
As head size has been shown to differ between individuals with
DS and typically developing individuals, we also investigated the
inﬂuence of ICV on brain-PAD. Indeed, DS participants did have
reduced ICV relative to controls (DS mean ¼ 1.19L [SD ¼ 0.11],
control mean ¼ 1.42L [SD ¼ 0.14], b ¼ 0.02, SE ¼ 0.03, t ¼ 7.89,
p < 0.001). However, ICV was not signiﬁcantly correlated with
brain-PAD in the DS group (r¼0.04, p¼ 0.77) or the control group
(r ¼ 0.09, p ¼ 0.62). There were no sex differences in brain-PAD in
either the DS group (t ¼ 0.66, p ¼ 0.51) or the control group
(t ¼ 1.00, p ¼ 0.32). APOE genotype did not signiﬁcantly inﬂuence
brain-PAD (t ¼ 1.63, p ¼ 0.11).3.4. Brain-predicted age increases are associated with increased PiB
binding potential
Within the DS group, 19 individuals were classiﬁed as PiB
positive based on PET data, whereas 27 individuals showed no
evidence of abnormal PiB binding (PiB negative). The mean cortical
PiB BPND across PiB-positive individuals ¼ 0.36  0.22, while the
median number of ROIs showing abnormal PiB levels in these in-
dividuals was 28 (range 1e30). Brain-PAD signiﬁcantly predicted
PiB-status in DS participants (b ¼ 0.20 [95% conﬁdence intervals ¼
0.03, 0.44], SE ¼ 0.10, z ¼ 1.98, p ¼ 0.048), as did chronological age(b ¼ 0.42, SE ¼ 0.14, z ¼ 3.11, p ¼ 0.002), in a logistic regression
model. The group mean brain-PAD scores were 5.29  9.41 years in
PiB-positive DS participants and 0.52  6.84 years in PiB-negative
DS participants (Fig. 3A). Brain-predicted age was signiﬁcantly
correlated with chronological age in PiB-positive individuals
(r ¼ 0.54, p ¼ 0.02), though this relationship was only borderline in
PiB-negative DS participants (r ¼ 0.32, p ¼ 0.08, Fig. 3B). Brain-PAD
signiﬁcantly predicted both mean cortical PiB BPND (b ¼ 0.008,
SE ¼ 0.003, t ¼ 2.78, p ¼ 0.001) and the number of ROIs showing
abnormal PiB levels (b ¼ 0.46, SE ¼ 0.14, t ¼ 3.40, p ¼ 0.001), when
covarying for chronological age (which was also signiﬁcantly
related to both quantitative PiB measures, p < 0.05) in DS
participants.3.5. Brain-predicted age increases are related to poorer cognitive
performance in PiB-positive individuals
When considering all DS participants together, there was a sig-
niﬁcant effect of brain-PAD on CAMCOG score (b¼0.80, SE¼ 0.35,
t¼2.24, p¼ 0.03), whereby higher brain-PADwas associatedwith
worse performance on the CAMCOG assessment. However, when
considering PiB status in the model, there was a signiﬁcant inter-
action between brain-PAD and PiB status (b ¼ 1.75, SE ¼ 0.72,
t ¼ 2.42, p ¼ 0.02), when predicting CAMCOG score (Fig. 4). This
indicates that in PiB-positive DS participants there is a strong
negative relationship between brain-PAD and CAMCOG score, while
in PiB-negative DS participants, there is no such relationship. This
was despite there being no signiﬁcant difference in CAMCOG score
based on PiB status, as noted above. Age was not included as a
covariate in these analyses as age was not related to CAMCOG score
(p ¼ 0.33). Ordinal logistic regression analysis indicated that brain-
PAD score did not signiﬁcantly predict CAMDEX classiﬁcation,
either with or without PiB status as an additional covariate
Fig. 3. Brain-predicted age in individuals with Down syndrome (DS), according to [11C]-PiB status. (A) Box plot of brain-PAD (years) according to [11C]-PiB status in DS participants.
PiB-positive (red box) and PiB-negative (white box). Whiskers (i.e., bars) on the box plots represent the absolute range of data points for each group. (B) Scatterplot of age (x-axis)
and brain-predicted age (y-axis) indicate PiB-positive DS participants (ﬁlled red circles) and PiB-negative DS participants (open red circles). Plotted are linear regression lines
representing a linear ﬁt of age regressed onto brain-predicted each, colored according to group (PiB-positive ¼ solid red line, PiB-negative ¼ dashed red line). Abbreviations:
[11C]-PiB, [11C]-Pittsburgh compound B; brain-PAD, brain-predicted age difference. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
Web version of this article.)
Fig. 4. Cambridge Cognitive Battery (CAMCOG) performance relates to brain-PAD,
according to [11C]-PiB status. Scatterplot of CAMCOG score (x-axis) against brain-
PAD (y-axis) in DS participants indicate PiB-positive individuals (ﬁlled red circles)
and PiB-negative individuals (open red circles). Plotted are linear ﬁt lines of CAMCOG
score regressed onto brain-PAD for each group (PiB-positive: solid line; PiB-negative:
dashed line), to illustrate the interaction between brain-PAD and PiB-status in pre-
dicting CAMCOG score. Abbreviations: [11C]-PiB, [11C]-Pittsburgh compound B; brain-
PAD, brain-predicted age difference. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the Web version of this article.)
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with declining or dementia ratings from the CAMDEX (i.e., limiting
the analysis to cognitively stable individuals, N¼ 31), there was still
a signiﬁcant effect of group on brain-PAD (b ¼ 7.34, SE ¼ 1.75,
t ¼ 4.19, p < 0.001). We then further investigated the relationship
between PiB status and CAMDEX classiﬁcation, though we
collapsed the CAMDEX into a binary classiﬁcation of stable versus
not stable (i.e., declining or dementia). There was a signiﬁcant
relationship between PiB-status and CAMDEX (p < 0.001), as DS
individuals were more likely to be stable if there were PiB-negative,
and more likely to be declining if they were PiB-positive (see
Supplementary Table 2). However, therewas nomain effect of these
subgroups on brain-PAD (p ¼ 0.23).
Finally, we considered how the magnitude of PiB-binding
(measured by mean BPND) and brain-PAD related to cognitive
impairment (i.e., CAMCOG score). A linear regression model
including mean BPND and brain-PAD as predictor variables and
CAMCOG score as the outcome was signiﬁcant (p ¼ 0.025) and
explained (R2 ¼) 12.6% of the variance in CAMCOG.
4. Discussion
Individuals with DS showed increased brain-PAD scores, indi-
cating that the three-dimensional patterns of brain volume asso-
ciated with DS resembled that of healthy individuals on average
2.49 years older. Moreover, the effect of DS on brain-PAD was an
adjusted increase of 7.69 years, compared to scanner matched,
typically developing controls. There was considerable variability
observed in brain-PAD in DS participants. Notably, this variability
related to measures of amyloid deposition, indexed by [11C]-PiB PET
imaging and to cognitive decline, according to CAMCOG
J.H. Cole et al. / Neurobiology of Aging 56 (2017) 41e49 47assessment. The relationship between brain-PAD and CAMCOG
score was observed only in individuals with evidence of amyloid
deposition, indicating that changes in brain structure and cognitive
performance may be linked to the deleterious build-up of amyloid
in DS.
This is the ﬁrst application of a neuroimaging-based “brain-
predicted age” index in people with DS. The observed increased
brain-PAD supports the idea that the long-term consequences of DS
include premature “age-like” changes to the structure of the brain.
Previously, studies have shown lower brain volumes or abnormal
cortical thickness in DS (Koran et al., 2014; Mullins et al., 2013;
Pinter et al., 2001; Romano et al., 2016; Teipel et al., 2004) as well
as a correlation between age and brain volume in individuals with
DS, not seen in controls (Beacher et al., 2010; Krasuski et al., 2002).
While these results have been used to indirectly infer the presence
of “accelerated” brain aging in DS, our machine learning method
provides a more direct approach of quantifying age-related changes
to brain structure, by way of reference to a large lifespan training
sample. Moreover, this technique captures voxel-wise variation in
brain volumes, incorporating higher resolution data into the pre-
diction, and is more appropriate for making individualized pre-
dictions, rather than relying on group-average trends. Crucially,
however, cross-sectional analysis can only suggest “premature” or
“accentuated” brain aging, which is a limitation of the current
analysis. Longitudinal studies are necessary to determine whether
these age-like changes to brain structure are static or are acceler-
ating over time.
Various mechanisms could underlie the increase in brain-PAD
observed in DS. One candidate is the triplication of the amyloid
precursor protein (APP) gene, found on chromosome 21, which
results in increased levels of APP (Rumble et al., 1989). As APP is
necessary for amyloid protein production, its overexpression may
result in increased amyloid levels and subsequent development of
neuritic plaques, a key risk factor for AD. Hence, APP triplication
may explain the earlier onset and higher prevalence of AD in DS. In
our study, PET-derived measures of the magnitude of ﬁbrillary beta
amyloid deposition were related to brain-PAD in DS participants,
when accounting for the age dependence of PiB levels (Hartley
et al., 2014). Conversely, brain-PAD did not relate to CAMDEX
classiﬁcation, though interestingly, a model containing brain-PAD
and mean PiB-binding signiﬁcantly predicted CAMCOG scores.
This highlights the convergence of amyloid deposition, structural
brain changes, and cognitive impairment in DS. While determining
causality from these cross-sections is not possible, our ﬁndings
suggest that the accumulation of ﬁbrillary beta amyloid may be a
precursor to the loss of brain tissue volume and cognitive changes,
with dementia symptoms manifesting later in the timeline of
neurodegenerative processes.
Other factors that potentially explain premature brain aging in
DS include the triplication of other genes on chromosome 21, such
as SOD-1 and SLC5A3, involved in response to oxidative stress and
in moderating cerebral myoinositol levels, respectively (Beacher
et al., 2010). Evidence also suggests that mitochondrial dysfunc-
tion occurs in DS in both peripheral and central cells (Phillips et al.,
2013; Tiano and Busciglio, 2011). Maintenance of mitochondrial
functions, particularly the production of ATP, is crucial to many
aspects of cellular function, and mitochondrial changes have been
implicated in aspects of aging (reviewed by Lopez-Otin et al., 2013).
Plausibly, mitochondrial dysfunction in neurons and astrocytes
caused by trisomy 21 could impact on the metabolism of APP
(Busciglio et al., 2002) and result in a cascade of downstream effects
that prematurely age brain structure in DS.
From an environmental perspective, physical health and
dietary factors, as evidenced by the increased rates of obesity
(Melville et al., 2005), may have indirect effects on physiological“wear-and-tear.” This could contribute to multiple aspects of aging
in DS, including the brain. Cerebrovascular factors, such as cerebral
amyloid angiopathy and microhemorrhages, perhaps as a result of
persistent neuroinﬂammation (Wilcock et al., 2016), may also be
involved. Such factors are thought to contribute to brain atrophy
outside of the context of DS (Chowdhury et al., 2011; Muller et al.,
2011); however, they are unlikely to be entirely independent of
the genetic and environmental issues discussed above. A cluster of
inter-related risk factors appears to be present in DS, negatively
impacting the neural milieu and hence increasing the rate of tissue
volume loss normally associated with aging.
Ours is not the ﬁrst study to assess the tissue-speciﬁc measure of
aging in DS. Previously, shortened lymphocyte telomere length has
been reported in people with DS (Jenkins et al., 2006; Vaziri et al.,
1993) and shorter telomeres have been associated with cognitive
decline and dementia status in DS (Jenkins et al., 2010, 2016).
Indices of age-associated oxidative stress have also been reported as
elevated in DS (Jovanovic et al., 1998). Recently, Horvath et al.,
(2015) reported “accelerated” epigenetic aging in people with DS,
using a multivariate method to predict age based on DNA methyl-
ation status in blood, buccal cells, and brain tissue. This indicates
that premature age-like changes are occurring at a molecular level
in individuals with DS, of which the reduced brain volume detected
by brain-predicted age may be a macroscopic manifestation.
Interestingly, the “residual” approach adopted by Horvath et al.,
which essentially sets the control groupmean to zero, resulted in an
average effect of DS equivalent to 6.6 years accelerated aging. Tak-
ing the same approach here, we see an effect of a similar magnitude,
7.4 years of added aging. In future studies, it could prove informa-
tive to combined multiple aging biomarkers (e.g., telomere length,
epigenetic clock, and brain-predicted age) to assess whether pre-
dictions of cognitive decline and dementia risk can be improved.
A potential criticism of neuroimaging models of brain-predicted
age is that results could be driven by deviation from normality, as
opposed to divergence along a speciﬁcally age-related trajectory.
While such deviations may occur in neurologic conditions, such as
stroke or encephalopathy, this is not the case in DS. Brain atrophy in
DS is likely to be gradual and cumulative, caused by factors such as
increased amyloid deposition or secondary effects of exposure to
abnormal neurodevelopment, rather than resulting from a one-off
insult. While DS brains have been shown to be abnormal in size
and morphology (Annus et al., 2017; Wang, 1996), brain-PAD scores
did not correlate with ICV, nor does ICV correlate with brain-PAD in
healthy individuals, so global size differences do not appear to be
driving the results. Distinctive brain morphology in DS also did not
seem to inﬂuence our ﬁndings as we observed no differences in the
MAE of age prediction in the DS and control groups; age prediction
accuracy was not hindered by any morphologic features of DS.
While, in general, it can be difﬁcult to distinguish between aging
effects and disease effects in conditions such as DS, the fact that
increased brain-PAD was seen when limiting the analysis to
cognitively stable (as per CAMDEX classiﬁcation) participants,
supports the idea that it is not manifest disease that is driving age-
related changes to brain structure.
Our study has some strengths and limitations. The use of a large
independent healthy training dataset (N ¼ 2001), on which the
brain-predicted age values were based, allowed us to put brain
aging in DS in context of what is expected in during healthy aging.
However, one limitation of acquiring these data from various public
sources is that we have inadequate demographic or behavioral data
from which to quantify the characteristics of these individuals,
other than that they were screened to be in good general and
neurologic health. The use of multimodal neuroimaging (i.e., MRI
and PET) to provide data on age-related brain changes in DS from
independent sources also adds to the strength of the ﬁndings. A
J.H. Cole et al. / Neurobiology of Aging 56 (2017) 41e4948general caveat to consider when conducting neuroimaging analysis
of individuals with DS is that when normalization is required, as in
this study, image registration performancemay be reduced, as brain
structure in DS is thought to be atypical. However, in this case, we
used SPM DARTEL to perform highly accurate nonlinear registra-
tions (Klein et al., 2009) and if registration error had been driving
the brain-PAD results, then this would increase noise and reduce
the sensitivity to relate brain-PAD to external measures such as
CAMCOG score. One perhaps surprising result is that the local
controls in the study showed signiﬁcantly “younger” appearing
brains, according to brain-PAD scores, relative to the independent
training sample. This could potentially be driven by scanner effects,
although by design the training sample includes individuals from a
range of different MRI scanner systems and ﬁeld strengths to dilute
any potential scanner biases that might cause overﬁtting and
reduce generalizability. Another explanation could be a recruitment
bias in that the local controls were comprised of individuals pref-
erentially exposed to positive inﬂuences on apparent brain aging,
although steps were taken to recruit a wide spectrum of controls
from beyond the conﬁnes of the University of Cambridge. We were
unable to acquire detailed demographic or behavioral data on these
individuals, so we could not ascertain whether the variance in
brain-PAD controls is related to any potential protective effects,
such as increased years of education or physical exercise. Finally, as
mentioned above, the cross-sectional nature of this study means
that we cannot examine trajectories of change in people with DS,
whichwould provide important information about the likelihood of
future neurologic decline and negative brain aging.
5. Conclusions
This multimodality neuroimaging study of DS indicates that a
consequence of trisomy 21 is an increase in structural brain aging,
detectable in middle adulthood. While longitudinal studies are
necessary to determine whether this increase in apparent brain
aging is static or accelerating, it is notable that the presence of
PiB-binding was related to increased brain-PAD and that in DS
participants with evidence of beta amyloid deposition, brain-PAD
related to cognitive decline. It seems that some people with DS
begin to show converging signs of potentially pathologic deterio-
ration, and that this can be detected using T1-weighted MRI to
index individual differences in brain aging. When no evidence of
PiB binding was observed, both brain aging and cognitive perfor-
mance remained unaffected. This could imply that amyloid depo-
sition, or related latent factor, could be driving the deleterious brain
changes associated with aging in DS.
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